Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.
Overview
Dividend investors are usually drawn like moths to high-yield stocks. That makes total sense, but a string of recent dividend cuts announced by companies like Conagra (NYSE: CAG) and Campbell's (NASDAQ: CPB) in the historically resilient consumer staples sector should leave dividend lovers on edge.
In the pharmaceutical space, another sector known for resilience, two of the highest-yielding stocks are Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO), with yields of 6% and 4.7%, respectively. Which one is the better choice?
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.